You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 201331 - 201340 of 207725 results
  1. RAPID AND SENSITIVE IDENTIFICATION OF HIV ANTIGEN AT THE POINT OF USE

    SBC: IMMUNETICS, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): HIV clade C, endemic in sub-Saharan Africa and the Indian subcontinent, is responsible for nearly half of all global HIV infections, and most large-scale HIV vaccine trials are targeted to clade C regions. Unfortunately, the development and trialing of candidate HIV vaccines brings with it the significant risk of vaccine-induced HIV seropositivity (VISP). VISP ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Enhancing protective antibody responses for a GM-CSF adjuvanted HIV vaccine

    SBC: PHOENIX BIOSYSTEM, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The success of HIV antibody tests in narrowing the window period of HIV diagnosis has been notable. However, immunoassays designed to detect antibody alone will not be able to identify individuals with acute infection who have not yet begun to produce HIV-specific antibodies. Attempts to detect acutely infected individuals have mostly involved RNA detection alg ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Development of Adult Pluripotent Very Small Embryonic Like (VSEL) Stem Cells to T

    SBC: Caladrius Biosciences            Topic: NIAMS

    DESCRIPTION (provided by applicant): Scleroderma is an autoimmune, connective tissue disorder which causes fibrosis of the skin and internal organs. In the skin, there is overproduction of extracellular matrix, and type 1 and 3 collagen. The disease involves vascular breakdown where the blood vessels in the skin degenerate and are replaced by collagen to form fibrotic tissue. The sclerotic tissue ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Novel Skin Protectant Retinoid for the Treatment of Psoriasis

    SBC: SUNNY BIODISCOVERY INC.            Topic: NIAMS

    DESCRIPTION (provided by applicant): Psoriasis is a chronic skin disease affecting 2% of the world population. It is characterized by immune infiltrates in lesions and hyperkeratosis, and can be partially remediated with prescription medicines, such as topical retinoids. Despite their great potential, current topical retinoid drugs are typically used at suboptimal doses, due to their side effect ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Healing of Diabetic Ulcers with Gaseous Nitric Oxide Generated from Room Air

    SBC: GLSynthesis Inc.            Topic: NIAMS

    DESCRIPTION: Androgen action is the net result of opposing pathways of steroid biosynthesis and metabolism. It is now widely recognized that testosterone (T) is an androgenic precursor of the more potent 5 -dihydrotestosterone (DHT), produced by 5 -reductase type 2. Circulating T and DHT also serve as precursors of estrogens through their conversion to estradiol and estrone by aromatase. Thus, re ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. CT-based Biomarker for Diagnosis of COPD Phenotypes and Disease Progression

    SBC: NAVIGEN, INC.            Topic: NIAMS

    DESCRIPTION (provided by applicant): Rheumatoid arthritis (RA) affects approximately 1.3 million adults in the United States and up to 1.5% of the population worldwide. In its progressive form the disease has debilitating effects including painful inflammation and destruction of the joints. This affliction leads to considerable lost work and disability. A hallmark of the RA inflammatory respon ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a cationic contrast agent for targeted imaging of glycosaminoglyca

    SBC: IONIC PHARMACEUTICALS, LLC            Topic: NIAMS

    DESCRIPTION (provided by applicant): There is no known cure for Osteoarthritis (OA), a debilitating disease that afflicts 27 million people and costs 125 billion, annually. In OA, the articular cartilage is degraded and it has a limited capacity to self-heal; therefore, rendering a diagnosis at a late stage is ineffective at preventing further cartilage degeneration. Currently, there are no contr ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Cartilage storage solution for chondrocyte viability and biomaterial preservation

    SBC: Cell & Tissue Systems, Inc.            Topic: NIAMS

    DESCRIPTION (provided by applicant): Resurfacing of articular cartilage with cold stored osteochondral allografts is employed clinically for repair of trauma and osteoarthritis-induced articular cartilage surface damage. Chondrocyte viability of transplanted articular cartilage is accepted as one of the determinants of outcome following osteochondral allograft transplantation. Refrigerated storage ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Sleeping Beauty Mediated Therapy for Alpha V Beta 6-Expressing Pancreatic Cancer

    SBC: LYNNTECH INC.            Topic: NIAMS

    DESCRIPTION (provided by applicant): Arthritis (AR) is the leading cause of disability in the United States, with 50 million Americans (22%) suffering from some form of the disease or chronic joint symptoms. The CDC estimates that, by the year 2030, 67 million adults will have AR and the economic burden will reach an annual cost of 128 billion dollars. While most AR cases are classified as osteoa ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Oral delivered bone building therapy for osteoporosis

    SBC: OsteoGeneX Inc            Topic: NIAMS

    DESCRIPTION (provided by applicant): The osteoporosis market is still in demand for new therapeutics due to the lack of safe orally available bone building drugs. Currently, parathyroid hormone (PTH; FORTEOTM) and its analogs are the only bone building therapies available yet they capture only 8% of the osteoporosis market due to significant dosing and safety limitations. OsteoGeneX is developing ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government